Partner Headlines - TEVA

  1. California Leads Nation In Tech, Lifesciences IPOs

    IBD
  2. Gurus Are Buying High-Yield Stocks Like WestRock, Target

    GuruFocus
  3. Top Stocks 2015: Biotechs, Wayfair, Netflix, Amazon

    IBD
  4. Takeda Provides Update About New Business Venture in Japan with ...

    Benzinga
  5. 5 Guru Picks in Volatile Biotech Industry

    GuruFocus
  6. NWQ Managers Reduces Stakes in Microsoft, MetLife and Teva Pharmaceutical

    GuruFocus
  7. Benzinga's Top Initiations

    Benzinga
  8. GoPro PT Cut; Chipotle, Bluebird Bio Downgraded

    IBD
  9. Benzinga's Volume Movers

    Benzinga
  10. Top Performing Industries For December 1, 2015

    Benzinga
  11. US Stock Futures Edge Higher Ahead Of Economic Data

    Benzinga
  12. Teva Announces Proposed Public Offerings Of Amer Depositary Shrs ...

    Benzinga
  13. Teva, Takeda Establish Partnership in Japan; Teva to Own 51% ...

    Benzinga
  14. Teva, Heptares Announce Agreement to Discover and Develop Novel, ...

    Benzinga
  15. Benzinga's Top Upgrades

    Benzinga
  16. Pfizer, Allergan Set To Unveil $150 Billion Inversion

    IBD
  17. John Paulson Increases Holding in Teva Pharmaceutical

    GuruFocus
  18. John Paulson Keeps Gold, Buys Drug Manufacturers in Q3

    GuruFocus
  19. Mylan, Perrigo Face Off As Takeover Vote Nears

    IBD
  20. Ronald Muhlenkamp's Highest-Yielding Stocks

    GuruFocus
  21. Teva Announces Breakthrough Therapy Designation for SD-809 Granted ...

    Benzinga
  22. Allergan Beats Q3 Estimates Amid M&A, Pricing Talk

    IBD
  23. Roche Touts New MS Drug As Legacy Players Hit Snags

    IBD
  24. Allergan Confirms Pfizer Talks

    IBD
  25. Teva Pharmaceutical's

    IBD
  26. Ah the Joys of Theft - My Purloined Portfolio

    GuruFocus
  27. Here's Why Biotechs Fell On Monday

    Benzinga
  28. Teva Launches Generic Avodart Capsules in the US

    Benzinga
  29. Neurocrine Tardive Dyskinesia Drug Hits, Stock Jumps

    IBD
  30. Acorda, Allergan Make Surprise Deal On Ampyra Patent

    IBD
  31. Benzinga's M&A Chatter for Thursday October 1, 2015

    Benzinga
  32. Allergan Guidance Update Gets Mixed Reception

    IBD
  33. U.S. M&A Hits Record As Companies Try To Grow Sales

    IBD
  34. Teva Announces COPAXONE Approved in Japan for Prevention of Relapse ...

    Benzinga
  35. Teva Presents New Reslizumab Data at ERS International Congress ...

    Benzinga
  36. Hedge Fund Menta Capital's Top Stocks Include Teva Pharmaceutical, ...

    GuruFocus
  37. An ETF That Provides Shelter From Stormy Markets

    Benzinga
  38. Teva Announces U.S. Availability of ZECUITY® (sumatriptan iontophoretic ...

    Benzinga
  39. Mylan Confirms USPTO Institutes Inter Partes Review Proceedings ...

    Benzinga
  40. Allergan Modestly Tops Views

    IBD
  41. Allergan Q2 Beats, But Generics Sale Clouds Outlook

    IBD
  42. Israeli Tech Startups Attract Record Funding In Q2

    IBD
  43. 5 Top Medical Stocks Reporting Earnings This Week

    IBD
  44. Teva's Deal-Making Spurs Inflows To Israel ETFs

    Benzinga
  45. Benzinga's Top Upgrades

    Benzinga
  46. IBD 50: 10 Top Stocks Reporting Earnings This Week

    IBD
  47. These 4 Foreign Drug Stocks Have Broken Out Recently

    IBD
  48. 5 Hot Drug Stocks Top IBD's Big Cap Leaders Screen

    IBD
  49. Wakefulness Drug Xyrem Keeps Jazz Pharmaceuticals Up

    IBD
  50. Amgen Stock Clears Buy Point Ahead Of Earnings

    IBD
  51. Stocks In Rebound Mode; Icon, Cadence Break Out

    IBD
  52. Can Health Care Sector Continue its Incredible Run?

    FoxBusiness
  53. Weekly 52-Week Highs Highlight: GIS, AAP, BCR, TEVA

    GuruFocus
  54. Benzinga's Top Upgrades

    Benzinga
  55. Teva Announces European Medicines Agency (EMA) Confirms Successful ...

    Benzinga
  56. Teva Prefers Allergan Unit

    IBD
  57. Benzinga's M&A Chatter for Monday July 27, 2015

    Benzinga
  58. Stocks Fall For Fifth Straight Session On China Woes

    IBD
  59. Allergan CEO: Teva Made A 'Compelling Offer' We Couldn't Refuse

    Benzinga
  60. Market Update: Monday's Top 10 Volume Movers

    Benzinga
  61. Stocks Mired In Red, Hurt By China Weakness; Boot Barn Bounces

    IBD
  62. Market Update: Monday's Mid-Day Movers, China's Stock Market ...

    Benzinga
  63. Stocks In The Red But Off Lows As Shanghai, Europe Weigh

    IBD
  64. Teva Drops Mylan Chase To Buy Allergan Generics Unit

    IBD
  65. Benzinga's Volume Movers

    Benzinga
  66. Teva Confirms Allergan Generics Buy, Drops Mylan Bid

    IBD
  67. U.S. Stocks On Track For Weak Open As Chinese Stocks Sink

    IBD
  68. UPDATE: Mylan Issues Comment on Teva Deal to Buy Allergan's Generic ...

    Benzinga
  69. UPDATE: Teva Withdraws Proposal to Acquire Mylan

    Benzinga
  70. UPDATE: Teva to Acquire Allergan Generics for $40.5 B

    Benzinga
  71. Benzinga's Weekend M&A Chatter

    Benzinga
  72. Teva To Buy Allergan's Generic Drug Unit, Unit Worth ~$45B, Deal ...

    Benzinga
  73. Biotech IPO Boom Gaining Thrust With NantKwest Debut

    IBD
  74. Morning-after pill use increases

    IBD
  75. Novartis' Mixed Q2: Sandoz Booms, Alcon Struggles

    IBD
  76. Rapid7 IPO Pops 52%; Investors Hungry For Blue Buffalo

    IBD
  77. Painkiller Abuse Drives Drugmakers To Innovate

    IBD
  78. Celgene Hits High As Street Applauds Receptos Buyout

    IBD
  79. Teva-Mylan merger opposed

    IBD
  80. Benzinga's Top Initiations

    Benzinga
  81. Medicines Co., Eagle Pharma Up On Analyst Actions

    IBD
  82. Momenta Pharma

    IBD
  83. Momenta Downgraded After Stock Price Doubles

    IBD
  84. Teva-Xenon Arthritis Pain Drug Fails Midstage Trial

    IBD
  85. Wednesday's Mid-Day Movers: Chubb, Rock Creed, RADA Win; Peabody ...

    Benzinga
  86. Unusual Covered Call Opportunity Teva Pharmaceuticals

    Benzinga
  87. Alder Bio Up As Credit Suisse Lauds Migraine Drug

    IBD
  88. New America's IPO Stock Winners: Fitbit, Arista

    IBD
  89. ObamaCare Enables Health Insurer Merger Mania

    IBD
  90. Paul Tudor Jones Buys Stakes in ADP and Visa

    GuruFocus
  91. Teva Migraine Drug Succeeds In Midstage Trial

    IBD
  92. Teva Migraine Drug Succeeds In Midstage Trial

    IBD
  93. Teva to Present New Findings at the American Headache Society ...

    Benzinga
  94. How High Can Eagle Pharmaceuticals Fly On Teva Deal?

    IBD
  95. Teva's Mylan bid hits snag

    IBD
  96. Teva's Auspex Buyout Pays, But Mylan Bid Hits Snag

    IBD
  97. Teva Advances Pipeline of Movement Disorder Assets with Announcement ...

    Benzinga
  98. Top Biotech Stock Files For New Drug, In Buy Range

    IBD
  99. Activist Hedge Fund Manager Has Strong Focus on Health Care Stocks

    GuruFocus
  100. New Migraine Drugs Could Ease Investors' Headaches

    IBD
Trading Center